The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 15 of the 47 sources its claims cite were checked for support.
Abstract
Background: Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synaptic dysfunction is an early feature in bvFTD and identification of specific biomarkers might improve its diagnostic accuracy. Our goal was to understand the differential diagnostic potential of cerebrospinal fluid (CSF) synaptic biomarkers in bvFTD versus PPD and their specificity towards bvFTD compared with Alzheimer’s disease (AD) and controls. Additionally, we explored the association of CSF synaptic biomarkers with social cognition, cognitive performance, and disease severity in these clinical groups. Methods: Participants with probable bvFTD (n = 57), PPD (n = 71), AD (n = 60), and cognitively normal controls (n = 39) with available CSF, cognitive tests, and disease severity as frontotemporal lobar degeneration-modified clinical dementia rating scale (FTLD-CDR) were included. In a subset of bvFTD and PPD cases, Ekman 60 faces test scores for social cognition were available. CSF synaptosomal-associated protein 25 (SNAP25), neurogranin (Ng), neuronal pentraxin 2 (NPTX2), and glutamate receptor 4 (GluR4) were measured, along with neurofilament light (NfL), and compared between groups using analysis of covariance (ANCOVA) and logistic regression. Diagnostic accuracy was assessed using ROC analyses, and biomarker panels were selected using Wald’s backward selection. Correlations with cognitive measures were performed using Pearson’s partial correlation analysis. Results: NPTX2 concentrations were lower in the bvFTD group compared with PPD (p < 0.001) and controls (p = 0.003) but not compared with AD. Concentrations of SNAP25 (p < 0.001) and Ng (p < 0.001) were elevated in patients with AD versus those with bvFTD and controls. The modeled panel for differential diagnosis of bvFTD versus PPD consisted of NfL and NPTX2 (AUC = 0.96, CI: 0.93–0.99, p < 0.001). In bvFTD versus AD, the modeled panel consisted of NfL, SNAP25, Ng, and GluR4 (AUC = 0.86, CI: 0.79–0.92, p < 0.001). In bvFTD, lower NPTX2 (Pearson’s r = 0.29, p = 0.036) and GluR4 (Pearson’s r = 0.34, p = 0.014) concentrations were weakly associated with worse performance of total cognitive score. Lower GluR4 concentrations were also associated with worse MMSE scores (Pearson’s r = 0.41, p = 0.002) as well as with worse executive functioning (Pearson’s r = 0.36, p = 0.011) in bvFTD. There were no associations between synaptic markers and social cognition or disease severity in bvFTD. Conclusion: Our findings of involvement of NTPX2 in bvFTD but not PPD contribute towards better understanding of bvFTD disease pathology.
Overview
CoChat Summary
TL;DR
In a memory-clinic cohort, CSF NPTX2 was lower in bvFTD than in PPD and controls, while SNAP25 and Ng were elevated in AD; biomarker panels including NfL discriminated bvFTD from PPD (AUC 0.96) and bvFTD from AD (AUC 0.86). Synaptic biomarkers showed limited added diagnostic value and weak or absent associations with social cognition and disease severity.
Key findings
- CSF NPTX2 concentrations were lower in bvFTD than PPD (p < 0.001) and controls (p = 0.003 in the abstract; p = 0.005 in the results), but not significantly lower than in AD.
- SNAP25 and Ng were elevated in AD compared with bvFTD, PPD, and controls (p < 0.001 for all); NfL was higher in bvFTD than AD, PPD, and controls (p < 0.001 for all).
- The selected panel for bvFTD vs PPD was NfL + NPTX2 (AUC = 0.96, CI 0.93–0.99, p < 0.001); for bvFTD vs AD it was NfL + SNAP25 + Ng + GluR4 (AUC = 0.86, CI 0.79–0.92, p < 0.001).
- In bvFTD, lower NPTX2 (r = 0.29, p = 0.036) and GluR4 (r = 0.34, p = 0.014) were weakly associated with worse total cognitive score; no synaptic marker correlated with social cognition or FTLD-CDR disease severity.
Methods
- Participants with probable bvFTD (n = 57), PPD (n = 71), AD (n = 60), and cognitively normal controls (n = 39) from the Alzheimer Center Amsterdam (2003–2021) had CSF, cognitive tests, and disease severity measures; Ekman 60 faces test scores were available for a subset (bvFTD n = 13; PPD n = 9).
- CSF SNAP25, Ng, NPTX2, GluR4, and NfL were measured; group comparisons used ANCOVA adjusted for age, sex, and psychotropic medication use, with logistic regression, ROC analyses, Wald’s backward selection for panels, and Pearson’s partial correlations controlling for age.
Limitations
- Stated: odds ratios for synaptic biomarkers were modest, and the clinical relevance of NPTX2 requires evaluation in larger cohorts; the PPD sample was heterogeneous, so disease-specific synaptic concentrations in PPD could not be assessed; sample sizes for cognitive test scores were limited, including social cognition, FTLD-CDR, and visuospatial functioning.
- Evident from the text: the bvFTD cohort had only mild-to-moderate disease severity (FTLD-CDR ≤ 16), limiting assessment across severity stages; GluR4 had higher assay variability (25% CV) than the other immunoassays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
8 Valid · 1 Not valid · 14 Not checked · 75 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For example, the AD-specific increase of CSF SNAP25 and Ng compared with bvFTD that we reported, corroborates previous findings [44,45].”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Discussion
What the sources say
- Partly supportedcites [44] Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neu- rogranin in the cerebrospinal fluid of patients with Alzheimer's disease. Alzheimer's Research & Therapy. 2022;14(1):58. sourceExperimental — accuracy not yet measured
Kivisäkk et al. (2022) do report higher CSF SNAP-25 (114±30 vs 71±24 pg/ml, p<0.0001) and Ng (418±142 vs 248±133 pg/ml, p<0.0001) in AD than in the pooled non-AD neurodegenerative (NeuroDegen) group, and their Abstract/Conclusions say SNAP-25 and Ng 'appear to be somewhat more specific for AD' — which supports the general drift of the claim. But the comparison is not with bvFTD: Table 1 lists a heterogeneous 'Frontotemporal dementia (FTD)' subgroup (n=18) within NeuroDegen, and the Statistical analysis section states that 'statistical analysis to determine differences in synaptic markers between the different neurodegenerative and non-neurodegenerative neurological diseases was not performed due to the large number of comparisons and small sample sizes.' Moreover the Discussion explicitly qualifies specificity the other way — 'Increased levels of the three synaptic proteins were, however, not specific to AD' — and credits the notion that Ng is increased specifically in AD rather than other neurodegenerative diseases to previous studies [20,21], not to its own data. The bvFTD-specific and 'AD-specific' parts of the claim are therefore not supported by this source. (LLM, conf=0.72)
- Not checked yetcites [45] Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzhei- mer's ResTher. 2019;11(1):105.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies have shown decreased synaptic density in the brains of FTD patients, particularly in brain regions affected by the disease including the salient network, inducing the characteristic impaired social cognition that is a hallmark feature of FTD [11].”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Discussion
What the sources say
- Partly supportedcites [11] Salmon E, Bahri MA, Plenevaux A, Becker G, Seret A, Delhaye E, et al. In vivo exploration of synaptic projections in frontotemporal dementia. Scientific reports. 2021;11(1):1-10. sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) does report that 'Extensive synaptic loss and reduction in the number of spines have been documented post-mortem in the diseased cortex' and a synaptophysin decrease in prefrontal cortex 'in some, but not all studies', and it credits the disrupted intrinsic connectivity network in bvFTD to anterior cingulate, frontal insula and striatum 'related to emotional salience processing' — so the salience-network framing is present but drawn from other works (refs 4, 8-11), not from this paper's own data. The paper's own in vivo result is only a non-significant trend: the Discussion states 'a trend for synaptic loss measured in vivo with SV2A-PET in the anterior parahippocampal gyrus', a region described as part of the 'social brain' involved in perception of socially salient stimuli, with no significant frontal synaptic loss. Nothing in our copy establishes that synaptic loss 'induces' impaired social cognition; the closest is the reported association (from ref 24) between atrophy — not synaptic density — in the perceptual social network and lack of attention to social cues, plus correlations of anosognosia with synaptic density in caudate and anteromedial prefrontal cortex. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, high levels of NfL are not specific to bvFTD as this biomarker can be strongly elevated in several other neurodegenerative conditions as well [2,40,41].”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Discussion
What the sources say
- Supportedcites [2] Del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh- Momoh C, et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022;18(11):2292-307. source
In the section 'Biomarkers to differentiate FTD from other dementias and non-degenerative disorders' our copy describes NfL as 'a general biomarker for neurodegeneration' and states that 'CSF NfL levels are increased in multiple related neurodegenerative disorders (e.g., ALS, PSP, multiple system [atrophy])', i.e. FTD should only be considered alongside a compatible clinical syndrome. The same section adds that reliance on general markers of neurodegeneration such as NfL 'highlight[s] the lack of well-established FTD-specific biomarkers', and the 'Challenges in the development of biomarkers for disease stage, prognosis, and drug efficacy' section repeats that serum NfL is 'a general marker of neurodegeneration' with similar changes in presymptomatic familial AD. The only nuance is that the source speaks of FTD/bvFTD-level specificity in general terms rather than bvFTD alone, but bvFTD is the phenotype it names for NfL's clinical use (differentiating bvFTD from primary psychiatric disorders, CONCLUSIONS). (LLM, conf=0.88)
- Could not verifycites [40] Ulugut H, Pijnenburg YAL. Frontotemporal dementia: past, present, and future. Alzheimers Dement. 2023;19(11):5253-63. sourceExperimental — accuracy not yet measured
Our copy of Ulugut & Pijnenburg (2023) mentions NfL only in passing in the INTRODUCTION, listing it among biomarkers ('greater emphasis on neurofilament light chain (NfL), TDP-43, plasma tau, p-tau, GFAP, and progranulin', refs 15-16), and Box 2 states only that 'Developing biological diagnostic biomarkers ... is an urgent need in FTD research' and that 'Tau-PET has limited value for distinguishing FTD'. No passage in our copy says that NfL elevation is not specific to bvFTD or that it is strongly raised in several other neurodegenerative conditions; searches for 'NfL not specific to bvFTD', 'neurofilament light chain elevated in ALS/Alzheimer's non-specific marker', 'biomarker specificity differential diagnosis' and 'lack of biological biomarkers' returned only these passing mentions. The paper is a historical/perspective review rather than a biomarker study, so this claim cannot be checked against it — nothing in our copy contradicts it either. (LLM, conf=0.70)
- Supportedcites [41] Illán-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, et al. Plasma tau and neurofilament light in frontotemporal lobar degen- eration and alzheimer disease. Neurology. 2021;96(5):e671-83. source
The Discussion of our copy states outright that 'NfL has emerged as a nonspecific CSF and plasma biomarker of neuronal injury in degenerative and nondegenerative disorders' and that plasma/serum NfL is elevated in both FTLD and AD versus healthy individuals, with weak discriminatory power between FTLD and AD or between FTLD clinical subtypes. The Results (Differences in Plasma t-Tau and NfL by Clinical Group; Diagnostic Value) give the magnitudes behind 'strongly elevated': FTLD-S 50.2 ± 31 pg/mL vs AD-S 28.5 ± 11 and HC 12.1 ± 4 (p < 0.001), highest in ALS-FTD (99.1 ± 46), with AUCs of 0.97 (FTLD-S vs HC) and 0.94 (AD-S vs HC). The paper also reports prognostic NfL value across bvFTD, svPPA, FTD-ALS and PSP subtypes, so treating NfL elevation as non-specific to bvFTD, extending to other neurodegenerative conditions, is what our copy says. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42].”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Discussion
What the sources say
- Partly supportedcites [42] Gómez de San José N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm (Vienna). 2022;129(2):207-30. https:// doi. org/ 10. 1007/ s00702-021-02411-2. sourceExperimental — accuracy not yet measured
Our copy supports the observational and general-mechanistic parts: the FTLD summary (Neuronal pentraxins in neurodegenerative, psychiatric and other disorders of the CNS) states an overall reduction of NPTXs in genetic and sporadic FTLD, with NPTX2 decreasing paralleling disease progression, and the Discussion states that NPTXs 'may contribute to the cognitive decline in neurodegeneration' via E/I imbalance and 'might promote or accelerate disease progression'. However, it does not attribute a crucial pathogenetic role in FTD specifically to NPTX2: for FTLD it frames the NPTX2 decrease as something that 'may reflect an association between synaptic disruption and cognitive impairment' (biomarker/reflection language), and the proposed-mechanism section explicitly leaves the causal question open — 'whether NPTXs actively contribute to neurodegeneration, or whether the deregulation of these proteins is a consequence of the synaptic damage' — reiterated in the Discussion ('Is the deregulation of NPTXs one of the pathological mechanisms ... or is it merely a consequence of the synaptic damage?'). The review also cautions that the alterations 'reflect a general pathological pattern and not a disease-specific mechanism', so the FTD-specific 'crucial role' overstates what this source says. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, clinical reports suggest that synaptic dysfunction precedes atrophy in patients with FTD [11,14], which highlights the need for novel biomarkers that may aid in earlier and more accurate diagnosis of bvFTD over PPD.”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Discussion
What the sources say
- Partly supportedcites [11] Salmon E, Bahri MA, Plenevaux A, Becker G, Seret A, Delhaye E, et al. In vivo exploration of synaptic projections in frontotemporal dementia. Scientific reports. 2021;11(1):1-10. sourceExperimental — accuracy not yet measured
The Introduction (Salmon et al., 2021) states only the general background that 'neuronal death in neurodegenerative diseases is preceded by disruption of synapses' and that synaptopathy/connectopathy have been described in FTLD on post-mortem work — it does not establish that synaptic dysfunction precedes atrophy in FTD patients. The Discussion instead says the opposite about ordering: atrophy staging 'was related to neuron loss and gliosis, and not to synaptopathy', and 'information is currently lacking on the sequence of pathological involvement of neurons ... and their synaptic projections'. The study's own in vivo data show a regional dissociation (a trend for lower [18F]UCBH uptake in the right anterior parahippocampal gyrus while atrophy was predominant in the ventromedial prefrontal cortex; Abstract/Discussion), not a temporal sequence, and the only 'before' finding it reports (plasma neuronal-derived exosome synaptotagmin/synaptophysin decreased before dementia diagnosis in bvFTD) is credited to another work (ref 50, Limitations). So the temporal-precedence part of the citing sentence is not supported by this source. (LLM, conf=0.72)
- Supportedcites [14] Malpetti M, Jones PS, Cope TE, Holland N, Naessens M, Rouse MA, et al. Synaptic loss in frontotemporal dementia revealed by [11C] UCB-J posi- tron emission tomography. Ann Neurol. 2023;93(1):142-54. https:// doi. org/ 10. 1002/ ana. 26543. source
The Discussion of Malpetti et al. (2023) states directly that, on comparing [11C]UCB-J binding with gray matter volumes, "the atrophy pattern in these patients was a subregion of the more widespread significant synaptic loss" and that one can "conclude that detectable synaptic loss precedes detectable atrophy in patients with bvFTD"; the Abstract Results likewise record "Synaptic loss was more severe than atrophy." The Introduction extends the point to the whole frontotemporal dementia spectrum ("early and severe synaptic loss, even preceding neuronal death and atrophy"), and the Discussion speaks of "early synaptic dysfunction" in the affected regions. The citing sentence is itself hedged ("clinical reports suggest"), matching the source's hedged framing, so the paraphrase is supported. (LLM, conf=0.85)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
55 more claims · 2 with their cited sources checked
Create a free account to see all 98 claims and to verify the 32 references still open.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, biomarkers relevant for bvFTD, such as neurofilament light chain in CSF and synaptic proteins such as Synaptophysin and GAP4398, 99, 100 were not available.”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > bvFTD versus PPD
“NPTX2 had the highest AUC (AUC= 0.72, CI: 0.63-0.81,p < 0.001) to discriminate bvFTD from PPD.”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Associations of the CSF synaptic biomarkers and NfL with cognition and disease severity
“NPTX2 0.71*** 0.62-0.8170.2 66.2 0.63* 0.52-0.7388.3 42.1”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Abstract
“NPTX2 concentrations were lower in the bvFTD group compared with PPD (p < 0.001) and controls (p = 0.003)”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Differential concentrations of candidate CSF biomarkers across the diagnostic groups
“NPTX2 concentrations were significantly lower in bvFTD compared with PPD (p < 0.001) and controls (p = 0.005).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Acknowledgements
“There was no financial or material support for this research”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Funding
“This research has received funding from the European Union's Horizon 2020 research and innovation Marie Curie program "MIRIADE" under grant agreement number 860197.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Acknowledgements
“there were no any potential conflicts of interest.”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Conflict
“Competing interests S.D., and J.G., are employees of ADx NeuroSciences, Gent, Belgium.E.V. is the co-founder of ADx NeuroSciences.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > bvFTD versus AD
“The AUC of NfL (AUC= 0.75, CI: 0.65-0.84,p < 0.001) was higher than all synaptic biomarkers except SNAP25.”
§ The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease > Associations of the CSF synaptic biomarkers and NfL with cognition and disease severity
“NfL 0.95*** 0.91-0.9981.0 95.8 0.76*** 0.66-.86 88.3 63.1”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“Several studies have reported the potential of NfL as a biomarker that correlates with brain atrophy, neurodegeneration, and cognition in dementias [17–20] and also with other neuronal damage, e.g., due to stroke, amyotrophic lateral sclerosis, and multiple sclerosis [3, 21–24].”
BackgroundSelf-citationNeurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334 · cited 1×
“NfL is a reliable biomarker of neuroaxonal damage and is used for the diagnosis (although limited due to its non-disease specificity), prognosis, and monitoring of treat-ment response in several neurodegenerative conditions [38].”
BackgroundMattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726 · cited 2×
“Several studies have reported the potential of NfL as a biomarker that correlates with brain atrophy, neurodegeneration, and cognition in dementias [17–20] and also with other neuronal damage, e.g., due to stroke, amyotrophic lateral sclerosis, and multiple sclerosis [3, 21–24].”
BackgroundImplementation of subjective cognitive decline criteria in research studies
Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., Ewers, M., Hampel, H., Klöppel, S., Rami, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.012 · Cited by 575 · cited 2×
“The diagnosis was concluded in a multidisciplinary meeting using consensus criteria for probable FTD, PPD (DSM-V), and AD [25, 31, 32].”
MethodWoolley, J. D., Khan, B. K., Murthy, N. K., Miller, B. L., & Rankin, K. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06382oli · Cited by 549
A practical guide to immunoassay method validation
Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00179 · Cited by 546 · cited 1×
“Synaptic protein Ng was measured using a commercial ELISA from EuroImmun, while the other synaptic proteins SNAP25, NPTX2, and GluR4 were measured using novel immunoassays developed and validated as per standardized protocols at ADx NeuroSciences, described in detail elsewhere [15, 36, 37].”
MethodSelf-citationThe epidemiology of frontotemporal dementia
Onyike, C. U., & Diehl-Schmid, J. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776523 · Cited by 543
Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management
Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70299-4 · Cited by 496 · cited 1×
“Moreover, we did not detect any association of the synaptic proteins or NfL with FTLD-CDR disease severity scores [53, 54].”
BackgroundDevelopment of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Advances in understanding the molecular basis of frontotemporal dementia
Rademakers, R., Neumann, M., & Mackenzie, I. R. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.117 · Cited by 412
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398
Self-citationDecreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398
Amsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Mackenzie, I. R. A., & Neumann, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13588 · Cited by 381
Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., et al. (2020) · Brain · doi:10.1093/brain/awaa018 · Cited by 320 · cited 3×
“…of the AD biomarkers amyloid-beta42, total tau, and phosphorylated tau181 to determine positive or negative AD biomarkers status (cutoffs applied as published elsewhere), electroencephalography and neuro- imaging-magnetic resonance imaging, and, if indicated, a [ 18 F]FDG-PET scan [3, 30].”
BackgroundMethodInfluentialSelf-citationPrimary Progressive Aphasia: Longitudinal Course, Neuropsychological Profile, and Language Features
Weintraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 310
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293
Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate
Represa, A., Deloulme, J., Sensenbrenner, M., Ben-Ari, Y., & Baudier, J. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-12-03782.1990 · Cited by 273
Lashley, T., Rohrer, J. D., Mead, S., & Revesz, T. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12250 · Cited by 220
Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
Varhaug, K. N., Torkildsen, Ø., Myhr, K.-M., & Vedeler, C. A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00338 · Cited by 185
Portelius, E., Olsson, B., Höglund, K., Cullen, N. C., Kvartsberg, H., Andreasson, U., Zetterberg, H., Sandelius, Å., Shaw, L. M., Lee, V. M. Y., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1851-x · Cited by 169
Zhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Verde, F., Otto, M., & Silani, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.679199 · Cited by 152
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease
Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011226 · Cited by 150
Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease
Groot, C., van Loenhoud, A. C., Barkhof, F., van Berckel, B. N. M., Koene, T., Teunissen, C. C., Scheltens, P., van der Flier, W. M., & Ossenkoppele, R. (2018) · Neurology · doi:10.1212/wnl.0000000000004802 · Cited by 143
Self-citationHenstridge, C. M., Sideris, D. I., Carroll, E., Rotariu, S., Salomonsson, S., Tzioras, M., McKenzie, C.-A., Smith, C., von Arnim, C. A. F., Ludolph, A. C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1797-4 · Cited by 135
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Katisko, K., Cajanus, A., Jääskeläinen, O., Kontkanen, A., Hartikainen, P., Korhonen, V. E., Helisalmi, S., Haapasalo, A., Koivumaa-Honkanen, H., Herukka, S.-K., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09567-8 · Cited by 112
The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia
DIEHLSCHMID, J., POHL, C., RUPRECHT, C., WAGENPFEIL, S., FOERSTL, H., & KURZ, A. (2007) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2007.01.024 · Cited by 111
Willemse, E. A. J., van Maurik, I. S., Tijms, B. M., Bouwman, F. H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J. J., Korf, E. S. C., van Marum, R. J., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.08.006 · Cited by 106
Self-citationKivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01002-x · Cited by 98
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94
Self-citationDhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93
Vijverberg, E. G. B., Wattjes, M. P., Dols, A., Krudop, W. A., Möller, C., Peters, A., Kerssens, C. J., Gossink, F., Prins, N. D., Stek, M. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160285 · Cited by 92 · cited 1×
“This leads to misdiagnosis in 50% of the cases with an average diagnostic delay of 6.4 years [3–5].”
BackgroundInfluentialSelf-citationGonzález‐Domínguez, R., Castellano‐Escuder, P., Lefèvre‐Arbogast, S., Low, D. Y., Preez, A. D., Ruigrok, S. R., Lee, H.-A., Helmer, C., Pallàs, M., Urpí-Sardà, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00948-8 · Cited by 61
Clarke, M. T. M., Brinkmalm, A., Foiani, M. S., Woollacott, I. O. C., Heller, C., Heslegrave, A., Keshavan, A., Fox, N. C., Schott, J. M., Warren, J. D., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0564-2 · Cited by 58 · cited 3×
“For example, the AD-specific increase of CSF SNAP25 and Ng compared with bvFTD that we reported, corroborates previous findings [44, 45].”
BackgroundResultDifferential expression of SNAP‐25 family proteins in the mouse brain
Yamamori, S., Itakura, M., Sugaya, D., Katsumata, O., Sakagami, H., & Takahashi, M. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22558 · Cited by 55
Different regions of synaptic vesicle membrane regulate VAMP2 conformation for the SNARE assembly
Wang, C., Tu, J., Zhang, S., Cai, B., Liu, Z., Hou, S., Zhong, Q., Hu, X., Liu, W., Li, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15270-4 · Cited by 55
Synaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53 · cited 4×
“Evidence from post-mortem and clinical studies including pre-dementia stages show that loss of synaptic function is a predominant early feature in bvFTD and correlates with the level of cognitive impairment [6–14].”
BackgroundMethodResultInfluentialdel Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Self-citationSynaptotagmins in Neurodegeneration
Glavan, G., Schliebs, R., & Živin, M. (2009) · The Anatomical Record · doi:10.1002/ar.21026 · Cited by 51
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50 · cited 4×
“…we found that concentrations of CSF synaptic biomarkers synaptosomal-associated protein 25 (SNAP25) and neu-rogranin (Ng) were elevated in FTD compared with controls, while those of neuronal pentraxin 2 (NPTX2) were lower than in controls, suggesting these could be valuable biomarkers for FTD [15].”
BackgroundMethodResultInfluentialSelf-citationEratne, D., Loi, S. M., Li, Q., Stehmann, C., Malpas, C. B., Santillo, A., Janelidze, S., Cadwallader, C., Walia, N., Ney, B., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12549 · Cited by 46
Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39 · cited 2×
“In agreement, using cerebrospinal fluid (CSF) biomarkers as indicators for synapse health, differential synaptic concentrations were found in genetic forms of FTD [12].”
BackgroundResultSelf-citationBolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36 · cited 1×
“Synaptic protein Ng was measured using a commercial ELISA from EuroImmun, while the other synaptic proteins SNAP25, NPTX2, and GluR4 were measured using novel immunoassays developed and validated as per standardized protocols at ADx NeuroSciences, described in detail elsewhere [15, 36, 37].”
MethodSelf-citationFrontotemporal dementia: Past, present, and future
Ulugut, H., & Pijnenburg, Y. A. L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13363 · Cited by 33 · cited 1×
“However, high levels of NfL are not specific to bvFTD as this biomarker can be strongly elevated in several other neurodegenerative conditions as well [2, 40, 41].”
BackgroundSelf-citationDas, S., Dewit, N., Jacobs, D., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Coppens, S., Quaglia, M., Hirtz, C., Teunissen, C. E., & Vanmechelen, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137221 · Cited by 26 · cited 1×
“NfL was measured using a novel ELISA developed at ADx NeuroSciences, described elsewhere [35].”
MethodSelf-citationIn vivo exploration of synaptic projections in frontotemporal dementia
Salmon, E., Bahri, M. A., Plenevaux, A., Becker, G., Seret, A., Delhaye, E., Degueldre, C., Balteau, E., Lemaire, C., Luxen, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95499-1 · Cited by 21
Cervantes González, A., Irwin, D. J., Alcolea, D., McMillan, C. T., Chen-Plotkin, A., Wolk, D., Sirisi, S., Dols-Icardo, O., Querol-Vilaseca, M., Illán-Gala, I., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00534-y · Cited by 19
Neurofilament light level correlates with brain atrophy, and cognitive and motor performance
Kartau, M., Melkas, S., Kartau, J., Arola, A., Laakso, H., Pitkänen, J., Lempiäinen, J., Koikkalainen, J., Lötjönen, J., Korvenoja, A., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.939155 · Cited by 16
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
Gómez de San José, N., Goossens, J., Al Shweiki, M. R., Halbgebauer, S., Oeckl, P., Steinacker, P., Danzer, K. M., Graf, H., Schönfeldt-Lecuona, C., Belbin, O., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.010 · Cited by 9 · cited 2×
“Simultaneously, another recent study suggested that patients with primary psychiatric disorders had significantly lower expression of the post-synaptic protein glutamate receptor 4 (GluR4) in CSF compared with cognitively normal controls and therefore could be useful as biomarkers for PDD [16].”
BackgroundResultSelf-citationWalia, N., Eratne, D., Loi, S. M., Farrand, S., Li, Q., Malpas, C. B., Varghese, S., Walterfang, M., Evans, A. H., Parker, S., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.15956 · Cited by 6
Research works printed but not linked: 1
- Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Alzheimers Dis. 2018;62(3):1091-1111. https:// doi. org/ 10. 3233/ JAD-170850. · DOI · Paper page
Cited by
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
Synapse vulnerability and resilience across the clinical spectrum of dementias
Taddei, R. N., & Duff, K. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01094-7 · Cited by 27
Hu, Q., Shi, M., Li, Y., & Zhao, X. (2024) · BMC Neurology · doi:10.1186/s12883-024-03728-7 · Cited by 21
Hazelton, J. L., Della Bella, G., Barttfeld, P., Dottori, M., Gonzalez-Gomez, R., Migeot, J., Moguilner, S., Legaz, A., Hernandez, H., Prado, P., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105614 · Cited by 14
“94 – 97 Further, biomarkers relevant for bvFTD, such as neuro fi lament light chain in CSF and synaptic proteins such as Syn-aptophysin and GAP43 98 – 100 were not available.”
Davydow, D. S., Brasfield, M., Morrow, C. B., Staffaroni, A. M., Pontone, G. M., & Asken, B. M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2429 · Cited by 9
Metadata
- Authors
- Das, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Amsterdam Neuroscience (NL)
- ADx NeuroSciences (BE)
- Corresponding author
- Verberk, Inge M. W.
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2024-02-14
- Volume
- 16
- Issue
- 1
- Pages
- 34-34
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC10865562
- OpenAlex
- W4391821162
- Cited by
- 12
- References
- 56
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Funders
- European Union's Horizon 2020 research and innovation Marie Curie program ‘MIRIADE’ (860197)
- Stichting Alzheimer Nederland
- Stichting Dioraphte
- ZonMW-funded PRODIA project (#ZonMW 733050206)
- Stichting VUmc
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- behavioral variant frontotemporal dementia, cerebrospinal fluid biomarkers, synaptic dysfunction, differential diagnosis, primary psychiatric disorders, Alzheimer's disease, NPTX2, SNAP-25, neurogranin, neurofilament light chain, social cognition, biomarker panel, disease severity, cognitive performance, frontotemporal lobar degeneration
- MeSH terms
- Alzheimer Disease, Humans, Neuropsychological Tests, ROC Curve, Biomarkers, Frontotemporal Lobar Degeneration, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.